NX 9
Alternative Names: NX-9Latest Information Update: 27 Jan 2022
At a glance
- Originator Nextrast
- Class Contrast media; Diagnostic agents
- Mechanism of Action Emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Gastrointestinal cancer; Gastrointestinal disorders
Most Recent Events
- 01 Dec 2021 Nextrast completes a phase II trial in Gastrointestinal disorders (Diagnosis) in USA (PO) (NCT04789200)